Efficacy and Safety of Personalized Transcranial Alternating Current Stimulation with different treatment frequencies for Major Depressive Disorder

Efficacy and Safety of Personalized Transcranial Alternating Current Stimulation with different treatment frequencies for Major Depressive Disorder: A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300078884

Enrollment

Unknown

Registered

2023-12-20

Start date

2023-12-20

Completion date

Unknown

Last updated

2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

major depressive disorder

Interventions

low-frequency fixed stimulation group:transcranial alternating current stimulation

high-frequency fixed stimulation group:transcranial alternating current stimulation

low-frequency individualized stimulation group:transcranial alternating current stimulation

high-frequency individualized stimulation group:transcranial alternating current stimulation

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1: Meeting DSM-V diagnostic criteria for major depressive disorder without psychotic symptoms 2: Age 18-55 3: No treatment with MECT/ECT, TMS, tDCS 1 month prior to enrollment 4: This episode was not systematically treated with antidepressants 5: 17-item Hamilton Depression Rating Scale (HAMD-17) score =17 at enrollment and HAMD-17 entry 1 (depressed mood) score =2 6: Have understood all aspects of the study and signed the informed consent form

Exclusion criteria

Exclusion criteria: 1: Meets DSM-V Other Psychiatric Diagnoses 2: Serious or unstable organic disease 3: Pregnant and breastfeeding women, patients unable to use suitable contraception during the trial period 4: History of seizures, epilepsy, hydrocephalus or CNS tumors, acute brain injury and infection 5: Impaired skin integrity at the electrode placement site, allergy to electrode gels or adhesives 6: With implantable electronic stimulator 7: Previous manic or hypomanic episodes 8: with a HAMD-17 3 (suicide) score of =3 9: Patients with prior suicidal behavior or existing strong suicidal ideation 10: Participants in any other clinical trial within 1 month prior to baseline 11: The researcher believes that there are circumstances that make participation in this study inappropriate 12: Researchers directly participating in this study or their immediate family members

Design outcomes

Primary

Measure	Time frame
effectiveness at the end of treatment;	—

Secondary

Measure	Time frame
Early effectiveness at 1 week;HAMD-17 factor scores;Effectiveness at 4 week;Changes in QIDS-SR16;Changes in GAD-7;Changes in HAMA;electroencephalography;Adverse event;	—

Countries

China

Contacts

Public ContactGang Wang

Beijing Anding Hospital

Adgangwang@163.com+86 10 5834 0320

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026